Competitive advantage, as it was understood for most of the 20th century, was assumed to be durable. Build a better manufacturing process or secure a valuable patent, and the advantage would compound for years. The strategic question was how to build the moat. The more interesting question — one that most strategy frameworks still underweight — is how long the moat actually holds.

The answer, increasingly, is: not as long as it used to.

The Traditional Sources and Their Erosion

Operational competitive advantages were built on proprietary workflows, production systems, and organizational capabilities that competitors could not easily replicate. Toyota’s production system is the canonical example — decades of organizational learning embedded in practices that no competitor fully reproduced even after the system became public knowledge.

Those kinds of operational advantages have become harder to sustain in the era of management consulting, talent mobility, and best-practice dissemination. What Toyota took twenty years to develop, a well-resourced competitor can approximate in three to five. The advantage does not disappear, but it compresses.

Technological competitive advantages historically came from patent protection, particularly in biopharmaceuticals where drug patents afforded meaningful exclusivity windows. This mechanism still works, but the context has changed. Patent cliffs arrive faster than they used to. Biologics biosimilar competition is accelerating. And in the technology-adjacent spaces where life sciences is increasingly operating — digital health, data analytics, AI-assisted drug discovery — patent protection is often weaker or slower to obtain than the pace of competitive development.

The uncomfortable conclusion: advantages built on operational or technological foundations that were durable for a decade in 1990 may be durable for three to five years today. The planning horizon for competitive advantage has compressed.

What Fills the Gap

If traditional sources of competitive advantage are eroding faster, what replaces them? The answer is not that competitive advantage disappears — it is that the sources of durable advantage shift toward things that are harder to commoditize.

Customer relationships, when deep enough to constitute genuine knowledge of customer workflows, purchasing criteria, and decision processes, create switching costs that are not captured in any financial statement but are very real. In life sciences, where purchasing decisions involve technical complexity, regulatory consequences, and long sales cycles, a supplier that has embedded itself into a customer’s development process has built something a competitor cannot replicate by offering a better price.

Proprietary data and accumulated insight are increasingly important. Organizations that have been operating in a market for years have built pattern recognition — about which customer archetypes adopt innovations, which market segments respond to which commercial approaches, which technical problems recur — that new entrants must build from scratch. This insight is not formally protected, but it is genuinely difficult to acquire.

Organizational culture and talent density in narrow domains — particularly in highly technical markets — create advantages that cannot be purchased outright. A team that has collectively worked through the same technical and commercial problems for years operates with a shared vocabulary and problem-solving intuition that is real but invisible on an organizational chart.

The Strategic Implication

The compression of competitive advantage lifespans does not mean that competitive strategy is less important. It means that the strategic conversation has to shift from “how do we build a durable moat?” to “how do we continuously generate new sources of advantage before the current ones erode?”

Organizations that treat competitive advantage as a stock — something to be built and protected — will find themselves defending positions that are increasingly difficult to hold. Organizations that treat competitive advantage as a flow — something that needs to be continuously generated through learning, customer proximity, and innovation — are better positioned for a market environment where advantage is real but not permanent.

In life sciences, this shows up practically: firms that have built technical sales capabilities, clinical insight, and customer relationships that compound over time tend to sustain commercial performance better than firms whose advantage is concentrated in a single product, technology, or cost structure.

MKA Point of View

We have observed this dynamic consistently across our client base. The clients who sustain performance over multiyear horizons are not the ones with the most defensible technology. They are the ones who have built the deepest understanding of their customers’ operational reality and the fastest internal feedback loops between market intelligence and strategic adjustment.

Competitive advantage in the 21st century is less a fortress and more a running start. Protecting it requires staying ahead, not building walls.